Nasdaq · Healthcare
Voyager Therapeutics, Inc. (VYGR)
As-reported financials and recent SEC filings for Voyager Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$40.4M
Net income
$-119.7M
Net margin
—
Diluted EPS
$-2.04
ROE
-61.1%
P/E (TTM)
—
Market cap
$216.9M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $40.4M | $80.0M | $250.0M | $40.9M | $37.4M |
| Gross profit | — | — | — | — | — |
| Operating income | $-131.8M | $-83.3M | $122.0M | $-50.8M | $-73.6M |
| Net income | $-119.7M | $-65.0M | $132.3M | $-46.4M | $-71.2M |
| Diluted EPS | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →Go deeper on VYGR
Search Voyager Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.